Palantir Bioceuticals, formerly IFAN Financial, Inc., (OTC: IFAN) is proud to announce their unique approach to mental health treatment. Palantir Bioceuticals is a biopharmaceutical company offering holistic solutions to mental health illnesses. Palantir Bioceuticals use a radical innovation called psychedelic-assisted psychotherapy (PAP), a supervised use of ketamine, MDMA, psilocybin, LSD and ibogaine as part of elaborated psychotherapy programs to treat depression, anxiety and PTSD.
Ketamine is legal, safe, and fast-acting when administered under medical supervision. Psychedelic exploration can create significant change after the first session. This unique therapy program combines psychedelics with therapeutic techniques to help patients discover the root causes of their pain. Our therapists help patients integrate the realizations from their psychedelic experience into daily life, ideally preventing relapse.
The traditional treatments for mental illness include antidepressants, antipsychotics, sleeping pills, minor tranquilizers, lithium, and other mood stabilizers. However, these medications have a wide range of side effects.
Research by Johns Hopkins’ Center for Psychedelic and Consciousness Research is at the forefront of exploring innovative treatments using psilocybin. Scientists and medical experts are now fully appreciating the effects of psilocybin on the brain and mind, and its potential as a therapeutic drug. Allied Market Research estimates that the global mental health market will grow by 3.5% from 2021 to 2030, reaching $537 billion in 2030.
Palantir Bioceuticals offers holistic alternatives to meet the growing demand for mental health solutions. Palantir Bioceuticals is committed to transforming mental health by gaining medical real estate properties and lease them to management companies committed to natural health and psychedelic psychotherapy.